Novavax Accounts Payable

Novavax (NVAX) currently reports a accounts payable of $23M as of June 2026. That compares with $51M in the prior-year period — down 54.7% year over year. Use the charts on this page to explore Novavax's accounts payable history and peer comparisons.

Novavax's accounts payable decreased from $51M to $23M — a 54.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Novavax reported $23M in accounts payable as of June 2026. That compares with $51M in the prior-year period — down 54.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $23M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Novavax, and consider following NVAX for alerts when major investors trade the stock.

Novavax is classified in the Healthcare sector. On accounts payable, it currently shows $23M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NVAX with unrelated industries.